Escherichia coli hemolysin has been implicated as a pathogenicity factor in extraintestinal E. coli infections including sepsis. In the present study the effects of intravascular administration of hemolysin were investigated in isolated blood-free perfused rabbit lungs. Low concentrations of the toxin in the perfusate (0.05-5 hemolytic units/ml, corresponding to 5-500 ng/ml), caused a dose-and time-dependent release of potassium, thromboxane A2, and prostaglandin I2, but not of lactate dehydrogenase, into the recirculating medium, as well as a dose-dependent liberation of the prostanoids into the bronchoalveolar space. These events were paralleled by a dose-dependent pulmonary hypertension, and studies with different inhibitors collectively indicated that the vasoconstrictor response was mediated predominantly by pulmonary thromboxane generation. In addition, E. coli hemolysin elicited a protracted, dose-dependent increase in the lung capillary filtration coefficient, which was independent of the prostanoidmediated pressor response and resulted in severe pulmonary edema formation. We conclude that E. coli hemolysin can elicit thromboxane-mediated pulmonary hypertension combined with severe vascular leakage in isolated lungs in the absence of circulating inflammatory cells and humoral mediator systems, mimicking the key events in the development of acute respiratory failure in states of septicemia.
Introduction
Bacterial sepsis is the most consistent factor associated with the development of the acute respiratory distress syndrome in adults, gram-negative aerobic rods currently representing the predominant infectious agents (1) (2) (3) (4) (5) . Moreover, acute diffuse (LPS) components of gram-negative bacteria (endotoxins) in intact animals, and detailed information is available on the mechanisms of lung injury by these agents. There is evidence for a critical role of circulating inflammatory cells, and activation of several humoral mediator systems (complement-and AA-cascade, reactive oxygen species, and proteases) has been documented (for review see references [12] [13] [14] [15] [16] . In contrast to endotoxins, bacterial exotoxins have received little attention as possible instigators of pulmonary dysfunction. A study on the action of E. coli hemolysin appeared especially warranted since many lines of evidence implicate this toxin as an important factor of bacterial pathogenecity in extraintestinal E. coli infections. Whereas hemolysin-producing strains are infrequently encountered in the normal fecal flora, 50% of E.
coli strains causing pyelonephritis and septicemia in humans are toxin producers, and hemolysin-producing strains also display enhanced virulence compared with isogenic nonproducers in various animal model infections (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . The toxin is secreted as a single chain polypeptide ofMr 107,000 (27) (28) (29) . Studies in erythrocytes and planar lipid membranes have shown that the hemolysin damages the cell membranes by insertion into the lipid bilayer and generation of a discrete, hydrophilic transmembrane pore with an effective diameter of 2 nm (30, 31 ). E. coli hemolysin was recently identified as a potent leucocidin (32) and reported to induce chemoluminescence response as well as enzyme and leukotriene release from human neutrophils in vitro (33) . In the present study we found that low doses of E. coli hemolysin are capable of mimicking key events of acute respiratory failure in blood-free perfused lungs, in particular TX-mediated pulmonary hypertension and vascular leakage. E. coli hemolysin may thus directly contribute to the pathogenesis of respiratory failure in states of septicemia or pneumonial infections with hemolysin-producing strains of this gram-negative rod.
Methods
Isolated lung protocol. The model of isolated rabbit lungs, originating from animals with a body weight between 2.2 and 2.8 kg, has been previously described (34) (35) (36) . Briefly, the lungs were ventilated with 4% C02, 17% 02, and 79% N2 (frequency, 45 strokes/min; tidal volume, 30 ml), and the endexpiratory pressure was set zero. They were perfused with Krebs Henseleit buffer in a recirculating system (circulating volume, 180 ml) with a pulsatile flow of 100 ml/min at 370C. In the standard protocol, the buffer contained 1 g % wt/vol bovine albumin. The alternate use of two perfusion systems allowed repeated exchanges of the perfusate by fresh buffer fluid. The left atrial pressure was set 2 mmHg under baseline conditions (0 referenced at the hilum) to guarantee zone III conditions at endexpiration throughout the lung. measured in the left atrium), peak inflation pressure, and the weight of the isolated organ were registered continuously. Only those lungs were selected for the study that (a) displayed a homogenous white appearance without signs of hemostasis or edema formation, (b) showed no spontaneous alteration of PAP or inflation pressure, and (c) were completely isogravimetric during a steady-state period of at least 45 min, during which the perfusion fluid was repeatedly exchanged. At the end of the steady-state period, remaining blood cells in the lung effluent ranged below 20/ti in all experiments. Random light microscopical examination of these lungs revealed virtually no erythrocytes or platelets, and few leukocytes in the vascular bed, and there was no evidence of interstitial edema or alveolar flooding. The wet to dry ratio of these lungs, corrected for the residual vascular volume, is known to lie in the physiological range (36) . E. coli hemolysin was admixed to the perfusion fluid before recirculation after termination of the steady-state period. The experiments were terminated 60 min after administration of the hemolysin, or when a hemolysin-induced lung weight gain exceeded 20 g total. Inhibitors of AA metabolism were dissolved in 100-200 ;l saline or ethanol and were also admixed to the buffer fluid before recirculation. The vehicles themselves are known to be ineffective in the small amounts used.
Capillary filtration coefficient (KfJ, vascular compliance, and bronchoalveolar lavage. Kfc was determined from the slope of weight gain, induced by a 7.5-mmHg step elevation ofthe venous pressure for 8 min. The application of this method to the present model has recently been described (36, 37) , and the time schedule is shown in Fig. 9 . Zero time extrapolation of the slope of weight gain, using a semilogarithmic plot of AW/At, was performed according to Taylor and Gaar (38) . KfC was calculated in terms of the elevation in venous pressure and expressed in cubic centimeters/millimeter Hg per gram wet lung weight per s X 10-'. The total vascular compliance, i.e., the change in the vascular volume per change in microvascular pressure, was determined from the initial rapid gain in lung weight after onset of the hydrostatic challenge (36) and is also given in terms of the venous pressure elevation (milliliters/millimeter Hg). A bronchoalveolar lavage ofthe entire lung with 30 ml saline total was performed at the end of the experiments as described (39) .
Detection of prostanoids. TXA2 and PGI2 were assayed by RIA from the recirculating buffer fluid and the bronchoalveolar lavage fluid as their stable hydrolysis products TXB2 and 6-keto-PGF, aph. as described (34, 40) . Lactatedehydrogenase and potassium in the perfusion fluid were measured according to standard techniques.
Preparation ofE. coli hemolysin. E. coli hemolysin was prepared by polyethylene glycol (PEG) precipitation of culture supernatant as described (30) . The precipitated protein was dissolved in saline, aliquotted, and stored lyophilized at -20°. The hemolytic titer was assessed directly before use and expressed in hemolytic units (HU)/milliliter (30) . The hemolysin protein concentration was determined by an ELISA that uses a monoclonal anti-hemolysin antibody to capture the antigen, and a second, polyclonal rabbit antibody for development (40a). The assay was calibrated with a toxin standard obtained by incorporation of E. coli hemolysin into phosphatidylcholin liposomes and subsequent isolation of the liposomes by flotation in a sucrose density gradient. The found that a hemolytic titer of I HU/ml corresponded to a toxin protein concentration of 0.1 g/ml. Two control reagents were used. First, E. coli hemolysin preparations were allowed to age for several hours at 370C; this led to rapid loss of cytolytic activity (30) Four experiments were additionally conducted with toxin preparations that had been depleted of LPS. The method used for preparing this toxin was an extension and modification ofa previously published procedure (42) and will be detailed elsewhere. In essence, PEG-precipitated toxin was dissolved in buffer and centrifuged twice over linear glycerol density gradients in a vertical rotor (type VTiG 5.1; Beckman Instruments, Inc., Palo Alto, CA). Each centrifugation was for 55 min at 220,000 g at 4VC. The toxin was recovered in active and monomeric form from the second gradient. The final product contained 4-6 yg/ml protein and 12-18 ng/ml residual LPS (i.e., -3 ng LPS/Mg protein). These preparations were applied at final dilutions of 1:600, corresponding to hemolysin concentrations of -8-10 ng/ml or 0.2 HU/ml (after gradient centrifugation the toxin exhibited slightly higher specific activity compared with the original PEG-precipitated toxin). The resulting LPS concentrations in the lung perfusate were then 20-30 pg/ml; these values were confirmed by endotoxin assays of the perfusate. (Fig. 1) . The magnitude of the pressor response was strictly dose dependent on the hemolysin concentration in the recirculating buffer fluid (Fig. 2) . When the buffer fluid was not exchanged, the hemolysin-induced pulmonary hypertension persisted for > 2 h; however, it was partly reversible upon rinsing the lung with toxin-free perfusate (example in Fig. 1 ). The pressor responses evoked by hemolysin concentrations up to 1.25 HU/ml were not accompanied by sustained alterations in lung weight. By contrast, the dramatic rises in PAP induced by 2.5-5 HU/ml perfusate were followed by a delayed, severe increase in lung weight. E. coli hemolysin caused a release of potassium, but not of LDH (< 10 U/liter), into the recirculating perfusate. The potassium liberation plateaued after 30 min and was again strictly dependent on the hemolysin concentration (Figs. [2] [3] [4] . When the buffer fluid was exchanged by hemolysin-free medium 30 min after toxin application, a partial reuptake of potassium by the lungs was observed, approximately 40-55% within 30 min.
The hemolysin-induced pressor response was accompanied by a rapid and dose-dependent release of TXB2 and 6-keto-PGF1 alpha into the recirculating medium ( the bronchoalveolar space (Fig. 6 ). The cyclooxygenase inhibitors indomethacin and acetylsalicylic acid reduced both toxinevoked prostanoid generation and pressor response to a great extent (Fig. 7) . In the presence of the TX synthase inhibitor OKY-046, both TX generation and pressure rise were blocked, whereas PGI2 liberation was unaffected. The TX receptor antagonist BM 13.177 inhibited the hemolysin-induced pressor response, but did not significantly influence the generation of both prostanoids. The slight depression of TX release in the presence of this specific receptor antagonist has already been observed in previous studies and may be explained by an interference with positive feedback mechanisms, i.e., interference with secondary AA metabolism and subsequent secondary TX formation by primarily induced TXA2 itself (43) (44) (45) . None of the four inhibitors of the AA system affected the hemolysininduced release of potassium.
Both prostanoid generation and pressor response noted after administration of E. coli hemolysin were strictly dependent on extracellular calcium. When this bivalent cation was omitted from the buffer fluid and EGTA was additionally admixed to the perfusate, E. cOli hemolysin still evoked potassium release to an undiminished extent; however, pressor re- coli hemolysin/ml perfusate: absence of perfusate exchange. The increase in the potassium concentration in the recirculating buffer fluid of seven isolated lungs exposed to 1.25 U hemolysin/ml is given. In these experiments the buffer fluid was not exchanged during the 2-h period.
sponse (example in Fig. 8 ) and prostanoid release were completely suppressed (TXB2 < 50 pg/ml and 6-keto-PGF1 alpha < 100 pg/ml in all experiments; n = 5 To differentiate between pressure-induced fluid filtration and increased microvascular permeability as possible causative factors of the edema formation after > 1.25 U hemolysin/ml, we took advantage of the nearly complete inhibition of any pressure rise by indomethacin. Performed in the presence of this cyclooxygenase inhibitor, a sequence of three hydrostatic challenges revealed a delayed, dose-dependent increase in the capillary filtration coefficient to severalfold values ( Fig. 9 ; Table I ). Since the vascular compliance was not augmented by the toxin, the manifold rise in KfC must be ascribed to a severe increase in hydraulic conductivity rather than to an increase in the capillary surface area. This vascular leakage induced by the hemolysin was not reversible upon rinsing the lungs with toxin-free buffer. At all doses used, E. coli hemolysin did not cause an increase in the peak inflation pressure of the isolated lungs. Only in the experiments with marked edema formation (> 10 g) a subsequent moderate rise occurred that was not further evaluated.
In an additional set of experiments E. coli hemolysin was administered to lungs perfused with Krebs Henseleit buffer in the absence of albumin as oncotic agent. In these lungs, the same features of dose-dependent potassium release, pressor response, and delayed increase in microvascular permeability were evoked by toxin doses approximating 1/25 of those used in the presence of albumin, i.e., by subhemolytic concentrations ranging between 0.05 and 0.2 HU/ml (Table II) . In four isolated lungs perfused with Krebs Henseleit buffer in the presence of 100 ,M acetylsalicylic acid according to the protocol given in Table II , hemolysin preparations with markedly reduced LPS content (-3 ng/sg protein) were used to give a final hemolysin concentration of 10 ng/ml, corresponding to 0.2 HU/ml, in the lung perfusate. The LPS content in these experiments was determined to be < 10, 20-30, and 20-30 pg/ml before, 5 min after, and 20 min after hemolysin application, respectively. The Kf,, values ofthese lungs were 2.2±0.3 before and > 10 30 min after hemolysin application and were thus not different from those noted in the corresponding experiments with hemolysin not reduced in LPS (Table II) . Additional control studies were performed using either aged, hemolytically inactive E. coli hemolysin preparations, or inactive 107,000 protein secreted by an isogenic E. coli strain lacking the hlyC gene. In both cases application of these preparations failed to elicit the described pressor response and vascular leakage (n = 3 each).
Discussion
The present study shows that E. coli hemolysin can dose-dependently induce severe alterations in lung physiology in the in lung physiology, i.e., potassium release, prostanoid generation, pressor response, and microvascular leakage. Finally, the use of toxin preparations that had been markedly depleted of LPS still led to unrestricted physiological pulmonary responses. In these experiments the endotoxin content was so low that final concentrations in the perfusate ranged between 20 and 30 pg/ml. Under no circumstances have such low concentrations of LPS ever been reported to evoke acute pulmonary reactions. Indeed, it is known from previous studies that even far larger amounts of endotoxin (> 1 sg/ml) do not provoke acute alterations in lung physiology or prostanoid generation in blood-free perfused isolated lungs (46-48; Seeger, W., unpublished data). The hemolysin-induced pressor response is a primary event and not secondary to lung edema formation. At toxin concentrations below 1.25 U/ml pulmonary hypertension occuffed without any significant gain in lung weight, and at higher toxin doses the rise in PAP clearly preceded the edema formation. Moreover, several recent studies have demonstrated that even large amounts oflung edema do not necessarily affect pulmonary vascular resistance (49) (50) (51) .
Pulmonary TX generation appears to be predominantly responsible for the toxin-induced vasoconstrictor response. There was a dose-effect relationship between applied toxin levels and concentrations of TXB2 in the recirculating medium and in the bronchoalveolar lavage fluid. Inhibitors of cyclooxygenase and TX synthase, as well as a TX receptor antagonist all significantly blocked the pressure rise. Furthermore, application of the stable TX analogue U-46619 provokes pressor responses in concentrations comparable to the TXB2 levels measured in the present study. The vasoconstrictive potency of TX evidently surpasses the vasodilatory effect of PGI2, which was co-released in comparable concentrations into the vascular and the alveolar compartment. The same finding has been made with a variety of other stimulatory agents in the rabbit lung model (52) .
The time course and magnitude of the hemolysin-induced pressor response were reminiscent of the acute pulmonary hypertension induced by Staphylococcus aureus alpha toxin (34) . The latter generates transmembrane pores of similar dimensions to those produced by E. coli (53, 54) . Studies in the rabbit lung (34), cultured pulmonary artery endothelial cells (55) , and granulocytes (56) collectively suggested that the toxin-cre- The lungs were perfused with Krebs Henseleit buffer without albumin, and the hemolysin was admixed to the perfusion fluid as described for the experiments in the presence of albumin. * AK gives the increase in the potassium concentration in the recirculating perfusate measured 30 min after application of E. coli hemolysin at the given concentrations. *APAP gives the maximum rise in mean PAP after administration of the hemolysin at the given concentrations in the absence of cyclooxygenase inhibition. § The Kfc was determined from three venous pressure challenges as described in Table I . These studies were performed in the presence of 100 1AM acetylsalicylic acid, which suppressed the hemolysin-evoked pressure rise to < 3 mmHg in all experiments. The ranges of baseline PAP, venous challenge-induced pressure rise, and vascular compliance did not differ among the given groups and did not differ from the data given in Table I for experiments in the presence of albumin.
then progressed unhaltingly and irreversibly, leading to pulmonary edema. This process was not dependent on lung prostanoid generation and pressure rise; the possible involvement of lipoxygenase metabolism of AA implicated in increased lung vascular permeability (36, 37, 52) , requires further investigation. The concentrations of E. coli hemolysin required to evoke acute alterations in the lung vasculature are remarkably low: 1-5 HU/ml (100-500 ng/ml) in the presence of circulating albumin, and 0.05-0.2 HU/ml (5-20 ng/ml) in protein-free perfusion fluid. Levels of the hemolysin produced by the present E. coli strain reach > 100 HU/ml after 4 h of growth in culture (40a). Although wild strains are generally weaker toxin producers, it is conceivable that toxin levels sufficient to induce pulmonary dysfunction may be attained during in vivo infections. Moreover, it has to be emphasized that the alterations in lung physiology were induced in the absence of granulocytes and humoral effector systems such as the complement cascade. As E. coli hemolysin was reported to activate granulocytes (32, 33) , the presence of these inflammatory cells may even amplify the detrimental effects of the toxin in the lung. E. coli hemolysin emerges as a potentially significant contributor to the pathogenesis of acute respiratory failure arising during severe infections with this important human pathogen.
